Stay on this psoriasis treatment, or switch?

I read NICE first. It assesses several things at once. The skin, the nails, high-impact sites, the effect on daily life, and any joint concerns. The International Psoriasis Council puts a topical-therapy mark in writing, and I compared the two. It counts topical therapy as failed when skin has not reached clear or almost clear after two courses in a row. The AAD and NPF guideline records methotrexate, apremilast, cyclosporine and acitretin as established systemic options considered in psoriasis care. I put the week marks and the method on measuring change, and the scores on how severe is yours.

What a treatment asks of you differs sharply by medicine, and I went through them one at a time. Blood tests and tuberculosis testing are typically required before a biologic starts, and biologics raise infection risk. Kidney function is checked before and during cyclosporine, and blood pressure is checked often. Apremilast requires no medical tests while you take it. Acitretin is contraindicated in pregnancy and carries a pregnancy-prevention requirement. AAD advises telling a dermatologist about pregnancy, pregnancy plans or breastfeeding before apremilast. Joints are a separate goal, and AAD records that biologics can stop psoriatic-arthritis pain, stiffness and swelling.

The National Psoriasis Foundation page I read says to bring a symptom tracker, on paper or on a phone, and to share it. It asks you to describe symptoms clearly and to note changes in severity and in the areas affected. Its flare guide offers a worksheet for daily symptoms and their severity. The Dermatology Life Quality Index already asks about symptoms and feelings, daily activities, leisure, work or study, and relationships. So the parts of your week that are not skin are already part of the record. I put the camera method on tracking flares and photos.

I read the NPF position statement. It adopted a two-class definition. Mild psoriasis can be managed with topical therapies. Moderate-to-severe psoriasis makes a person a candidate for advanced therapies. NPF states that moderate-to-severe psoriasis is not determined solely by body surface area involvement of 10%. Psoriasis on a high-impact site counts, and NPF names the face, scalp, hands, feet, nails and genitals. So does an inability to get adequate control from topicals. NICE reads the skin, the nails, those sites, daily life and joint concerns together.

Whether topical steroids are safe over the long run, or will thin skin or stop working, is one of the questions psoriasis readers ask most. I read the NPF on the stopping half of it. It records that abruptly stopping a topical steroid can cause a psoriasis flare. It also records that guidance advises checking with a clinician rather than using one for a long stretch. AAD lists starting a medication among its reported flare triggers, and names strong corticosteroids there. So a medicine can move psoriasis on the way in and on the way out. AAD also records that triggers differ from person to person. I put what is known about psoriasis moving on its own on will it clear or flare.

The 2019 NPF patient survey I read found that 41% of people with psoriatic disease had gone through step therapy. By NPF count, more than 25 states have passed a step-therapy law. That law gives a patient a way to ask for an exception, and NPF wants the same process in every state. NPF also offers a Patient Navigator for personalized help getting the treatment you need. I put what a request looks like, and what to keep, on prior authorization and step therapy.